Amgen Inc. (AMGN)
Amgen Inc. (AMGN) Q2 2025 Earnings Call Transcript
Amgen Inc. (NASDAQ:AMGN ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants & - Corporate Participant James E. Bradner - Executive Vice President of Research Development Justin G.
Amgen (AMGN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Amgen (AMGN) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Amgen (AMGN) Beats Q2 Earnings and Revenue Estimates
Amgen (AMGN) came out with quarterly earnings of $6.02 per share, beating the Zacks Consensus Estimate of $5.26 per share. This compares to earnings of $4.97 per share a year ago.
Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?
Let's look at five pharma and biotech companies, PFE, LLY, AMGN, GILD and NVO, which are scheduled to release their second-quarter 2025 results this week.
Buy or Sell Amgen Stock Ahead of Its Earnings?
Amgen (NASDAQ:AMGN) is set to release its earnings on Tuesday, August 5, 2025. Historically, Amgen's stock has shown a tendency to experience negative one-day returns following its earnings announcements.
Gear Up for Amgen (AMGN) Q2 Earnings: Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Amgen (AMGN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2025.
Amgen Gears Up to Report Q2 Earnings: Will the Beat Streak Continue?
AMGN eyes another earnings beat as strong drug volumes offset pricing pressure and biosimilar headwinds.
Amgen (AMGN) Reports Next Week: Wall Street Expects Earnings Growth
Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amgen (AMGN) Just Flashed Golden Cross Signal: Do You Buy?
Amgen Inc. (AMGN) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, AMGN's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
Amgen (AMGN) Stock Falls Amid Market Uptick: What Investors Need to Know
Amgen (AMGN) reached $301.29 at the closing of the latest trading day, reflecting a -1.73% change compared to its last close.
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Amgen vs. Novo Nordisk: Which Pharma Giant Is the Better Buy?
AMGN's deep pipeline and rare disease expansion may outweigh NVO's GLP-1 dominance and leadership shakeup.
